EGIS 8237
Latest Information Update: 15 Aug 2007
At a glance
- Originator Egis Pharmaceuticals
- Class Anti-ischaemics; Piperazines; Pyrimidines
- Mechanism of Action Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ischaemic heart disorders
Most Recent Events
- 07 Apr 1998 New profile
- 07 Apr 1998 Preclinical development for Ischaemic heart disorders in Hungary (Unknown route)